Nephrology, Tajimi Hospital, Tajimi, Japan
Nephrology, Tajimi Hospital, Tajimi, Japan.
BMJ Case Rep. 2022 Mar 15;15(3):e248927. doi: 10.1136/bcr-2022-248927.
Systemic capillary leak syndrome (SCLS), also known as Clarkson's disease, is a rare disorder of unknown aetiology. Since SCLS was first described in 1960, fewer than 500 cases have been reported. SCLS is diagnosed by the classic triad of hypotension, haemoconcentration and hypoalbuminaemia resulting from fluid extravasation. Some reports show that SCLS may sometimes occur as a side effect of adenoviral vector COVID-19 vaccines, although there is only one report (two cases) of SCLS after receiving a messenger RNA vaccine. Survival rates for SCLS are very poor without treatment, so it is crucial for clinicians to recognise this disorder. A middle-aged woman who presented with generalised malaise and anasarca after receiving the BNT162b2 COVID-19 vaccine was diagnosed with SCLS. Treatment with methylprednisolone and intravenous immunoglobulin was commenced and her symptoms resolved. We expect that this case report will add to the existing literature on this rare disorder and the side effects of vaccinations.
全身性毛细血管渗漏综合征（SCLS），也称为Clarkson 病，是一种病因不明的罕见疾病。自 1960 年首次描述 SCLS 以来，报告的病例少于 500 例。SCLS 的诊断依据是低血压、血液浓缩和低白蛋白血症三联征，这是由于液体外渗所致。一些报告表明，SCLS 可能有时是腺病毒载体 COVID-19 疫苗的副作用，尽管只有一份报告（两例）在接种信使 RNA 疫苗后出现 SCLS。如果不治疗，SCLS 的生存率非常差，因此临床医生识别这种疾病至关重要。一名中年女性在接种 BNT162b2 COVID-19 疫苗后出现全身不适和全身性水肿，被诊断为 SCLS。开始使用甲泼尼龙和静脉注射免疫球蛋白治疗，她的症状得到缓解。我们希望本病例报告将为这一罕见疾病及其疫苗副作用的现有文献增添内容。
